Extensions

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) can extend the term of a U.S. patent to compensate for certain delays caused by the USPTO during the examination process. These delays include failing to: issue a first office action or notice of allowance within 14 months of filing; respond to an applicant's reply within four months; act on an appeal decision within four months; or issue a patent within four months of the issue fee payment. Additionally, PTA is granted if the application is pending for more than three years, excluding applicant-caused delays.

The Google Patents page for US12447128B2 does not explicitly state any Patent Term Adjustments. To determine the exact PTA, a detailed review of the patent's prosecution history in USPTO Patent Center would be necessary.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is available for patents on certain human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products to restore time lost during the regulatory review process for premarket government approval. The extension is limited to a maximum of five years, and the total patent life with a PTE cannot exceed 14 years from the date of FDA approval. Only one patent can be extended per regulatory review period for a given product.

The Google Patents page for US12447128B2 does not explicitly state any Patent Term Extensions. Given that enzalutamide (marketed as XTANDI®) is a drug, this patent could be eligible for PTE. However, a specific application for PTE would need to be filed and approved by the USPTO in conjunction with the FDA.

Continuation Applications, Divisional Applications, and Related Family Members

The Google Patents page for US12447128B2 lists the following related application numbers:

• US17/985,220 (Application number for US12447128B2 itself)
• US202217985220A (Another format for the application number)
• US20230122911A1 (Other version / publication number)

The patent text explicitly states that US12447128B2 claims priority to US17/985,220. In general, for applications filed on or after June 8, 1995, a patent granted on a continuation, divisional, or continuation-in-part application will have a term that ends twenty years from the filing date of the earliest application for which a benefit is claimed.

Projected Expiration Date

The "Prior art date" for US12447128B2 is September 11, 2012, and the "Filing date" of the application is November 11, 2022. The "Publication date" is October 21, 2025. The Google Patents page for US12447128B2 indicates an "Anticipated expiration" date of September 11, 2033.

The general rule for utility patents filed on or after June 8, 1995, is that the patent term begins on the date the patent issues and ends 20 years from the date on which the application was filed, or 20 years from the earliest filing date if it claims priority to an earlier application. The anticipated expiration date of September 11, 2033, aligns with 20 years from the "Prior art date" of September 11, 2012, which the patent likely claims as its earliest effective filing date for term calculation purposes. Without specific information on PTA or PTE from the USPTO official records, the anticipated expiration date provided by Google Patents is the most reliable current estimate.